Veeva Systems (NYSE:VEEV) Price Target Cut to $317.00 by Analysts at Wells Fargo & Company

Posted by Caroline Horne on Mar 5th, 2026

Veeva Systems (NYSE:VEEV – Get Free Report) had its target price decreased by research analysts at Wells Fargo & Company from $333.00 to $317.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the technology company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 63.50% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. UBS Group lifted their target price on Veeva Systems from $200.00 to $220.00 and gave the company a “neutral” rating in a research report on Thursday. Royal Bank Of Canada cut their price objective on shares of Veeva Systems from $330.00 to $275.00 and set an “outperform” rating on the stock in a research report on Thursday. Needham & Company LLC decreased their target price on shares of Veeva Systems from $355.00 to $270.00 and set a “buy” rating for the company in a research report on Thursday. BTIG Research reissued a “buy” rating and set a $340.00 price target on shares of Veeva Systems in a research report on Friday, November 21st. Finally, JPMorgan Chase & Co. decreased their price objective on Veeva Systems from $330.00 to $296.00 and set an “overweight” rating for the company in a report on Friday, February 20th. Nineteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $288.12.

Check Out Our Latest Report on VEEV

Veeva Systems Price Performance

VEEV traded up $5.40 during mid-day trading on Thursday, hitting $193.88. The stock had a trading volume of 2,334,939 shares, compared to its average volume of 2,224,579. Veeva Systems has a 1-year low of $168.13 and a 1-year high of $310.50. The firm has a market capitalization of $31.87 billion, a price-to-earnings ratio of 37.72, a price-to-earnings-growth ratio of 1.28 and a beta of 1.09. The stock’s fifty day simple moving average is $204.58 and its 200-day simple moving average is $248.39.

Veeva Systems (NYSE:VEEV – Get Free Report) last issued its quarterly earnings data on Wednesday, March 4th. The technology company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. The business had revenue of $835.95 million for the quarter, compared to the consensus estimate of $810.95 million. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The firm’s revenue was up 16.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.74 EPS. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. As a group, research analysts expect that Veeva Systems will post 4.35 earnings per share for the current fiscal year.

Veeva Systems announced that its board has approved a stock buyback plan on Monday, January 5th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the technology company to buy up to 5.5% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total transaction of $231,430.00. Following the transaction, the insider owned 23,204 shares in the company, valued at $5,370,101.72. This trade represents a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of Veeva Systems

Several institutional investors and hedge funds have recently bought and sold shares of VEEV. Linden Thomas Advisory Services LLC increased its holdings in shares of Veeva Systems by 0.3% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 12,444 shares of the technology company’s stock valued at $3,707,000 after acquiring an additional 35 shares during the period. Sigma Planning Corp boosted its stake in shares of Veeva Systems by 1.2% during the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock worth $958,000 after buying an additional 39 shares during the period. Personal CFO Solutions LLC grew its holdings in shares of Veeva Systems by 3.5% during the third quarter. Personal CFO Solutions LLC now owns 1,163 shares of the technology company’s stock worth $346,000 after buying an additional 39 shares during the last quarter. AFT Forsyth & Company Inc. increased its position in Veeva Systems by 4.2% in the 3rd quarter. AFT Forsyth & Company Inc. now owns 984 shares of the technology company’s stock valued at $293,000 after acquiring an additional 40 shares during the period. Finally, Williams Jones Wealth Management LLC. raised its stake in Veeva Systems by 0.4% during the 3rd quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company’s stock valued at $2,806,000 after acquiring an additional 40 shares during the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

Positive Sentiment: Q4 beat and bullish guidance — Veeva reported ~$836M in Q4 revenue (vs. ~811M est.) and $2.06 EPS (vs. ~1.94 est.), then issued FY27 and Q1 guidance above consensus; that fundamental beat-and-raise is the primary catalyst lifting the stock. Veeva Announces Fourth Quarter and Fiscal Year 2026 Results
Positive Sentiment: AI / CRM growth story strengthening — management signaled CRM could be ~10% of revenue by 2030 and highlighted agentic/AI momentum as a driver for product uptake, supporting longer-term revenue expansion. Veeva signals CRM to comprise 10% of revenue by 2030 as AI momentum builds
Positive Sentiment: Supportive analyst moves — small target upgrades from UBS (200→220) and Morgan Stanley (205→215) and positive press coverage (Barron’s highlighted Veeva as positioned to withstand AI disruption fears) add conviction to the rally. Analyst note: UBS/Morgan Stanley actions (Benzinga) Veeva Systems Stock Rallies After Earnings (Barron’s)
Neutral Sentiment: Mixed analyst revisions — several firms trimmed lofty price targets (e.g., Piper Sandler, Needham, RBC) but many maintained buy/overweight stances, leaving sizable implied upside ranges even after cuts; this creates mixed short-term sentiment but doesn’t erase the beat-and-raise narrative. Piper Sandler / TickerReport Benzinga: analyst price target changes
Negative Sentiment: Some analysts trimmed forecasts and flagged competitive/CRM pressures — headlines note that a subset of analysts reduced their forecasts after Q4 and investors are watching disclosures about competitive losses in CRM-related markets, which tempers the post-earnings optimism. These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results (Benzinga) Veeva Retreated Following Management’s Competitive Losses Disclosure (Yahoo)

Veeva Systems Company Profile

(Get Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.